Enfermedad renal crónica (ERC) felina

Qué podría notar

• Toma mucha más agua: se queda junto al grifo, en la ducha o en el bebedero del perro, y deja bolitas más grandes o más numerosas en la arena.
• Pierde peso poco a poco y usted lo nota con las manos antes que en la báscula: la columna, las caderas y los omóplatos se sienten huesudos aunque todavía coma.
• Come menos de lo habitual, o se acerca al plato, lo huele y se va. Algunos gatos empiezan a rechazar comida que siempre les gustó.
• El pelo se ve opaco, aplastado, grasoso o descuidado, porque se acicala menos.
• Duerme más, se esconde más, salta menos y en general se interesa menos por lo que pasa en la casa.
• Vomita, a veces de forma intermitente durante semanas, y el aliento huele raro, como a químico o a amoníaco, más que solo a mal aliento.
• Estreñimiento: heces más pequeñas, duras y secas, o puja en la caja sin lograr mucho, porque al cuerpo le falta agua.
• La cabeza y el cuello se le caen hacia abajo, con el mentón cerca del pecho, o parece que no puede sostener la cabeza. Es un signo reconocido de potasio bajo en la sangre, algo frecuente en la ERC felina, y requiere un análisis de sangre, no esperar a ver qué pasa.
• Encías o párpados internos pálidos y se cansa muy rápido, lo que puede significar anemia.

Estándar de atención

1. Feed a therapeutic renal diet - the intervention with the best-designed trial in feline CKD, with its stage limits stated

   Aprobado / respaldado por guías

   The diet evaluated in the pivotal trial is described by its own authors as 'a renal diet modified in protein, phosphorus, sodium, and lipid content'. Commercial veterinary renal diets are more fully characterised elsewhere as reduced in protein, phosphorus and sodium, potassium- and B-vitamin-replete, alkalinising, and containing n-3 fatty acids - that fuller description belongs to Bartges 2012 (PMID 22720808) and must be cited there, not to the trial. STAGE THRESHOLD, because it matters: the trial enrolled IRIS stage 2 and 3 cats only. Dietary phosphate restriction is the component with a rationale from stage 2 onward; PROTEIN restriction in an IRIS stage 1 cat is NOT supported by this trial, and unnecessary protein restriction in an early-stage or already-thin cat risks the sarcopenia and weight loss that this protocol elsewhere treats as the endpoint that matters most. Decide by stage, body condition and appetite, not reflexively at diagnosis. Transition slowly, over weeks rather than days, offering the new food alongside the old; a renal diet the cat refuses has zero effect size, so palatability and a stress-free feeding set-up are part of the prescription, not an afterthought. Warm the food, offer wet and dry versions of the same product, and never withhold food to force the change in a cat that is already losing weight - a cat that stops eating is at risk of hepatic lipidosis.

   CAT DATA, RANDOMISED CONTROLLED TRIAL, IRIS STAGE 2-3 ONLY. Double-masked, randomised, controlled clinical trial in 45 client-owned cats with spontaneous IRIS stage 2 or 3 CKD, evaluated trimonthly for up to 24 months. Uraemic episodes occurred in 26% of cats on the adult maintenance diet versus 0% on the renal diet, with a significant reduction in renal-related deaths. Be precise about the limits: the comparator was one adult maintenance diet, not a drug; the reduction in ALL-CAUSE death was not significant; and body weight, haematocrit, UPC and serum creatinine, potassium, calcium and PTH did not differ significantly. It is the best-designed trial in the field. It is not a head-to-head win over telmisartan, benazepril, phosphate binders or capromorelin, and must not be written as one.

   Ross SJ, Osborne CA, Kirk CA, Lowry SR, Koehler LA, Polzin DJ. Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats. J Am Vet Med Assoc. 2006;229(6):949-57. PMID 16978113. Renal-diet composition as described in: Bartges JW. Chronic kidney disease in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(4):669-92. PMID 22720808, https://doi.org/10.1016/j.cvsm.2012.04.008

2. Stage and substage before you prescribe anything, and restage rather than guess

   Aprobado / respaldado por guías

   IRIS stage from at least two stable creatinine values, substaged by UPC and systolic blood pressure. The ISFM panel's central practical point is that the manifestations of CKD vary between individuals, so therapy must be prioritised and adjusted to the individual patient - a cat in stage 2 with proteinuria and hypertension and a cat in stage 2 with neither do not get the same prescription. When several therapies are indicated at once, the panel explicitly frames prioritisation around what is likely to most benefit that individual patient and around maintaining quality of life, which it calls of paramount importance.

   CONSENSUS GUIDELINE, CATS. The ISFM consensus panel reviewed the published literature and graded the quality of evidence for each intervention in feline CKD - the same discipline this page applies. Staging framework: International Renal Interest Society CKD staging guidelines.

   Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, Langston C, Lefebvre HP, White J, Quimby J. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016;18(3):219-39. PMID 26936494. Staging: International Renal Interest Society, http://www.iris-kidney.com/guidelines/

3. Measure blood pressure and treat systemic hypertension - and be exact about which regulator approved what

   Aprobado / respaldado por guías

   Hypertension in CKD cats damages eyes, brain, heart and the kidneys themselves, and is easy to miss because routine blood pressure monitoring is performed infrequently. Follow the 2018 ACVIM consensus statement for measurement technique, thresholds, target-organ assessment and treatment decisions. TWO AGENTS, TWO DIFFERENT REGULATORY POSITIONS, AND THE DIFFERENCE MUST BE STATED. (1) Telmisartan oral solution (Semintra, 10 mg/mL) is FDA-approved with the verbatim indication 'SEMINTRA is indicated for the control of systemic hypertension in cats', NADA 141-501, 'For oral use in cats only', dosed per the US label at 1.5 mg/kg PO q12h for 14 days then 2 mg/kg PO q24h, with the label's own titration instruction: 'The dose may be reduced by 0.5 mg/kg (0.23 mg/lb) increments to a minimum of 0.5 mg/kg (0.23 mg/lb) orally once daily to manage SEMINTRA-induced hypotension.' A separate EMA authorisation for Semintra exists (EMEA/V/C/002436), but PetSmartMeds did not read its indication text at source in this pass and publishes no EU label wording. (2) Amlodipine besylate is what the ISFM hypertension guidelines call, verbatim, 'the treatment of choice to manage feline hypertension and is effective in the majority of cats, but the dose needed to successfully manage hypertension varies between individuals'. It has NO FDA feline approval located in this research pass - it appears instead on FDA's List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals for dogs, cats and horses (listed 19 January 2023), which is a compounding-enforcement list, not an approval. So in the United States amlodipine in a cat is EXTRA-LABEL use of a guideline-preferred drug, and must never be described as 'approved'. One published feline case report describes reversible gingival hyperplasia attributed to amlodipine, which resolved after switching to telmisartan (Desmet 2017, PMID 29270307) - a single case report, so look for it and report it, but do not present it as a known incidence rate. HUMAN SAFETY, SEMINTRA US LABEL, VERBATIM: 'Pregnant women should avoid contact with SEMINTRA because substances that act on the renin-angiotensin-aldosterone system (RAAS) such as angiotensin receptor blockers (ARBs) can cause fetal and neonatal morbidity and death during pregnancy in humans.' Ask who in the household will dose the cat before you dispense it. Recheck blood pressure, creatinine and potassium after starting or changing any antihypertensive, and tell the owner not to adjust the dose at home.

   TWO GUIDELINES PLUS ONE FDA-APPROVED FELINE LABEL PLUS ONE CASE REPORT. Acierno 2018 is an ACVIM consensus statement covering identification, evaluation and management of systemic hypertension in DOGS AND CATS. Taylor 2017 is the ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in CATS (PubMed article type: Practice Guideline) and is the source of the amlodipine 'treatment of choice' wording. The telmisartan indication, NADA number, species restriction, dose and titration instruction above are quoted from the current US label. The amlodipine adverse-effect note is a single case report and is labelled as one.

   Acierno MJ, Brown S, Coleman AE, Jepson RE, Papich M, Stepien RL, Syme HM. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018;32(6):1803-1822. PMID 30353952. Taylor SS, Sparkes AH, Briscoe K, Carter J, Cervantes Sala S, Jepson RE, Reynolds BS, Scansen BA. ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats. J Feline Med Surg. 2017;19(3):288-303. PMID 28245741, https://doi.org/10.1177/1098612X17693500. Desmet L, van der Meer J. Antihypertensive treatment with telmisartan in a cat with amlodipine-induced gingival hyperplasia. JFMS Open Rep. 2017;3(2):2055116917745236. PMID 29270307, https://doi.org/10.1177/2055116917745236. Semintra US label (NADA 141-501): https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f436a826-9f5b-4269-b4ec-97d5522eaca6. Amlodipine compounding listing: FDA, List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Nonfood-Producing Animals, https://www.fda.gov/animal-veterinary/animal-drug-compounding/list-bulk-drug-substances-compounding-office-stock-drugs-use-nonfood-producing-animals

4. Quantify and reduce proteinuria - an evidence-supported use, not a US label claim

   Ensayo controlado en esta especie

   Magnitude of proteinuria is one of the factors reported as related to progression of established feline CKD, so UPC is a number to act on, not just record. Renin-angiotensin-aldosterone blockade with telmisartan or benazepril is the usual approach. JURISDICTION AND LABEL SCOPE: the US telmisartan indication is control of systemic hypertension in cats (FDA, NADA 141-501); reducing proteinuria in CKD is an evidence-supported clinical use in the United States, NOT an FDA label claim, and no FDA feline approval for benazepril was located in this research pass either. Do not start either drug in a dehydrated or acutely decompensating cat, recheck creatinine and potassium shortly after starting, and read the nephrotoxic-combination step below before adding an NSAID or a diuretic on top.

   CAT DATA, RANDOMISED CONTROLLED NON-INFERIORITY TRIAL, n=224, MANUFACTURER-SPONSORED AND CO-AUTHORED. Prospective, multicentre, randomised, blinded, parallel-group non-inferiority trial in 224 client-owned adult cats with CKD, allocated 1:1 to telmisartan 1 mg/kg PO q24h or benazepril 0.5-1.0 mg/kg PO q24h. Telmisartan was NON-INFERIOR to benazepril for controlling proteinuria (CI -0.035 to 0.268) - non-inferior, which is not a claim of superiority and not a claim of equal efficacy on every outcome. At day 180 the change in UP/C from baseline was significantly lower in the telmisartan group (-0.05 +/- 0.31; P=0.016) whereas the benazepril change (-0.02 +/- 0.48) was not significant (P=0.136); the same pattern held at all assessment points. Both drugs were well tolerated. CONFLICT OF INTEREST, DISCLOSED: three of the five authors are employees of Boehringer Ingelheim, which markets telmisartan as Semintra - the drug the trial favours and this page recommends. Honest framing: this trial measured PROTEINURIA, not survival. Progression-factor context: Brown 2016, PMID 26869151.

   Sent U, Gossl R, Elliott J, Syme HM, Zimmering T. Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015;29(6):1479-87. PMID 26474314. Author affiliations (Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim Animal Health GmbH) are stated on the article itself.

5. Control phosphorus

   Aprobado / respaldado por guías

   Dietary phosphorus intake is one of the factors the pathology review reports as related to progression, and phosphorus overload is among the factors implicated in initiation - associations, stated as associations, not demonstrated drivers. Dietary phosphate restriction comes first and is already built into a renal diet; intestinal phosphate binders are added when diet alone does not bring plasma phosphate into the IRIS stage-based target range, guided by serial measurement rather than fixed dosing.

   NARRATIVE REVIEW PLUS CONSENSUS GUIDELINE, CATS. Brown 2016 (PubMed article type: Journal Article, Review) identifies phosphorus overload among factors implicated in initiation and dietary phosphorus intake among factors 'related to progression' of established feline CKD; it does not adjudicate causal direction and neither does this page. The ISFM consensus guidelines set out the graded therapeutic approach, including phosphate restriction and binders. The renal-diet RCT that produced the survival-relevant benefit used a phosphorus-restricted formulation, so phosphorus control is part of the intervention that actually has trial support.

   Brown CA, Elliott J, Schmiedt CW, Brown SA. Chronic Kidney Disease in Aged Cats: Clinical Features, Morphology, and Proposed Pathogeneses. Vet Pathol. 2016;53(2):309-26. PMID 26869151. Management: Sparkes AH et al. J Feline Med Surg. 2016;18(3):219-39. PMID 26936494.

6. Protect hydration and potassium - and never supplement potassium without a measured value

   Ensayo controlado en esta especie

   Water intake, multiple wide water stations, wet food, and - where the individual patient and owner tolerate it - subcutaneous fluid therapy at home. Hypokalaemia is common in feline CKD and is corrected with oral potassium gluconate or citrate, GUIDED BY MEASUREMENT, which means: do not start, increase or continue a potassium supplement without a current measured serum potassium, and do not let an owner dose it by feel. THE CEILING MATTERS AS MUCH AS THE FLOOR. A cat on a RAAS blocker (telmisartan or benazepril) has reduced aldosterone-driven potassium excretion, so potassium supplementation on top of RAAS blockade risks hyperkalaemia; recheck potassium after starting or changing either the drug or the supplement. FLUIDS ARE NOT DOSE-FREE EITHER. Use caution with subcutaneous fluid volumes in any cat with concurrent cardiac disease, consider screening the heart before sending fluids home, and give the owner the breathing red flag in writing - fast, laboured or open-mouth breathing after fluids is a same-hour emergency. Tell the owner in plain words to call before changing the fluid volume or frequency. Be explicit about the evidence grade here: the ISFM panel graded interventions and these supportive measures do not carry the trial support that the renal diet does, so they are individualised and reassessed rather than applied as a fixed protocol.

   CONSENSUS GUIDELINE, CATS, LOWER EVIDENCE GRADE THAN DIET. The ISFM consensus panel graded the quality of evidence for different interventions in feline CKD and stresses repeat evaluation with adjustment to individual needs. Management of CKD-associated comorbidities including hypertension, proteinuria and anaemia is covered in a narrative review of CKD in DOGS AND CATS (Bartges 2012). The hyperkalaemia caution follows from the mechanism of RAAS blockade and from the requirement in both sources that electrolytes be monitored rather than assumed; no feline trial of potassium supplementation on top of RAAS blockade was located in this research pass, so it is stated as a monitoring rule, not as a quantified risk.

   Sparkes AH et al. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016;18(3):219-39. PMID 26936494. Bartges JW. Chronic kidney disease in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(4):669-92. PMID 22720808, https://doi.org/10.1016/j.cvsm.2012.04.008

7. Defend appetite and body weight - there is an FDA-approved drug for exactly this, and it has label limits

   Aprobado / respaldado por guías

   Weight and appetite are the endpoints owners can see and the ones that track quality of life most closely. CAPROMORELIN ORAL SOLUTION (ELURA), a ghrelin-receptor agonist from Elanco, is FDA-approved under NADA 141-536 (approved 19 October 2020) with the indication, verbatim: 'For management of weight loss in cats with chronic kidney disease.' Keep the CKD qualifier - dropping it broadens an approved drug's claim beyond its label. Label limits that must travel with the recommendation: CONTRAINDICATED in cats with a hypersensitivity to capromorelin; ANIMAL SAFETY WARNINGS state do not use in cats with hypersomatotropism (acromegaly), that it may increase serum glucose for several hours after dosing, and that use in cats with diabetes mellitus has not been evaluated; keep the bottle secured away from other animals. Note carefully that the acromegaly statement is an animal safety warning, not a labelled contraindication, and must not be upgraded into one. MIRTAZAPINE TRANSDERMAL OINTMENT 2% (MIRATAZ) is FDA-approved under NADA 141-481 with the indication, verbatim: 'Mirataz is indicated for body weight gain in cats with a history of weight loss' - note that this indication does NOT name CKD - applied as a 1.5-inch ribbon to the inner pinna once daily for 14 days. THE MIRATAZ PRECAUTION WRITTEN FOR THIS EXACT POPULATION, VERBATIM: 'Use with caution in cats with kidney disease. Kidney disease may cause reduced clearance of mirtazapine which may result in higher drug exposure.' Also verbatim: 'Use with caution in cats with hepatic disease. Mirtazapine may cause elevated serum liver enzymes' and 'Mirataz should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor (MAOI).' OWNER HANDLING, MIRATAZ LABEL, VERBATIM: 'Wear disposable gloves when handling or applying Mirataz to prevent accidental topical exposure' and 'After application, care should be taken that people or other animals in the household do not come in contact with the treated cat for 2 hours because mirtazapine can be absorbed transdermally and orally.' In case of accidental skin exposure wash thoroughly with soap and warm water; for eye exposure, flush with water. Dispense gloves with the tube and say all of this out loud. Beyond drugs: control nausea and pain, reduce clinic and household stress, and do not postpone an oesophagostomy feeding tube out of squeamishness in a cat that is losing ground - the ISFM inappetence panel states that postponing such interventions to await improvement MAY hinder recovery and worsen nutritional deficits (their hedge, preserved), while also flagging refeeding syndrome as a complication. That guideline is scoped to the inappetent HOSPITALISED cat.

   TWO FDA-APPROVED FELINE LABELS, ONE RANDOMISED PLACEBO-CONTROLLED FELINE TRIAL, PLUS A FELINE GUIDELINE. Elura: NADA 141-536, FDA CVM approval announcement 19 October 2020; indication, contraindication and animal safety warnings quoted from the current US label (DailyMed setid be4beb9c-f39b-4b23-9c35-f72a049a3250). Most frequently observed adverse effects vomiting and hypersalivation, more common in male cats, with transient decreases in heart rate and blood pressure and transient increases in blood glucose in safety studies. Trial support for the feline indication: randomised, masked, placebo-controlled multicentre field study in 176 client-owned cats with EXISTING CKD and unintended weight loss of 5% or more, randomised 2:1 to capromorelin or vehicle placebo orally once daily for 55 days. In the effectiveness population (n=112), mean body-weight change from day 0 to day 55 was +5.18% (95% CI 3.45-6.91) with capromorelin and -1.65% (95% CI -3.82 to 0.55) with placebo; treatment effect +6.81% (95% CI 4.21-9.42), P<0.0001, about +0.25 kg (95% CI 0.15-0.35). Hypersalivation occurred only in the capromorelin group (P<0.0001); for all other adverse events there was no significant between-group difference, but note the raw burden - at least one adverse event was reported in 96/118 (81.4%) capromorelin cats and 41/58 (70.7%) placebo cats. Two of the three authors are Elanco employees, which is disclosed here. Mirataz: NADA 141-481, current US label (DailyMed setid 5ff9fdb7-554f-4f91-8cfc-6d05094384c6); indication, precautions, MAOI statement and human-handling warnings quoted verbatim.

   FDA CVM Update: FDA Approves Elura (capromorelin oral solution) for Managing Weight Loss in Cats with Chronic Kidney Disease, 19 October 2020; Elura US label, NADA 141-536, DailyMed setid be4beb9c-f39b-4b23-9c35-f72a049a3250. Wofford JA, Milliken MacKinnon A, Heinen E. Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial. J Feline Med Surg. 2025;27(11):1098612X251379924. PMID 41204815, https://doi.org/10.1177/1098612X251379924. Mirataz (mirtazapine transdermal ointment) US label, NADA 141-481, DailyMed setid 5ff9fdb7-554f-4f91-8cfc-6d05094384c6. Taylor S, Chan DL, Villaverde C, Ryan L, Peron F, Quimby J, O'Brien C, Chalhoub S. 2022 ISFM Consensus Guidelines on Management of the Inappetent Hospitalised Cat. J Feline Med Surg. 2022;24(7):614-640. PMID 35775307, https://doi.org/10.1177/1098612X221106353

8. Assess and manage the anaemia, and treat the other diseases the kidneys are hiding

   Ensayo controlado en esta especie

   Anaemia is among the factors reported as related to progression of established feline CKD, so it is assessed and managed rather than merely observed. This page does not assert which way the arrow points: the source reports an association and does not adjudicate direction, and anaemia in CKD is at least partly a consequence of the disease. The same visit should re-ask what else is going on: hyperthyroidism can mask CKD and vice versa, and treating hyperthyroidism lowers GFR and unmasks azotaemia. Iatrogenic hypothyroidism is a recognised complication of ALL treatment options for feline hyperthyroidism and increases the risk of azotaemia; levothyroxine therapy is recommended for cats that are hypothyroid and azotaemic. Remember also that telmisartan's own US label states it can cause mild or non-regenerative anaemia and that cats should be monitored for anaemia - so a falling PCV in a CKD cat on Semintra has at least two candidate explanations.

   TWO NARRATIVE REVIEWS - ONE IN CATS, ONE IN DOGS AND CATS. Anaemia as a factor related to progression: Brown 2016, PMID 26869151 (PubMed article type: Journal Article, Review). Comorbidity management including anaemia: Bartges 2012, PMID 22720808 (Journal Article, Review; its title and scope are 'Chronic kidney disease in DOGS AND CATS'). Thyroid-renal interaction and the levothyroxine recommendation: Geddes & Aguiar 2022, PMID 35481810 (Journal Article, Review - a narrative comorbidity review, NOT a consensus guideline). Neither review is a guideline and this page does not label either as one.

   Geddes R, Aguiar J. Feline Comorbidities: Balancing hyperthyroidism and concurrent chronic kidney disease. J Feline Med Surg. 2022;24(7):641-650. PMID 35481810. Bartges JW. Vet Clin North Am Small Anim Pract. 2012;42(4):669-92. PMID 22720808. Brown CA et al. Vet Pathol. 2016;53(2):309-26. PMID 26869151. Telmisartan anaemia warning: Semintra US label, NADA 141-501.

9. Choose pain control with the kidney numbers in front of you - do not leave a CKD cat in pain by default, and do not let an owner improvise it

   Aprobado / respaldado por guías

   Most CKD cats also have degenerative joint disease, and under-treating that pain is a real harm, not a cautious choice. The 2024 ISFM/AAFP NSAID guidelines exist precisely for this decision: screen before prescribing, use a feline-licensed NSAID at the lowest effective dose, monitor efficacy and renal parameters, and account for interactions with the other CKD drugs. THE OWNER RULE COMES FIRST, BECAUSE IT IS THE ONE THAT KILLS CATS. Never give a cat human pain or fever medicine: not acetaminophen / paracetamol (Tylenol), not ibuprofen (Advil, Motrin), not naproxen (Aleve), not aspirin, and not a combination cold or flu product containing any of them. And never give a cat a medicine dispensed for a dog - canine NSAIDs such as carprofen, dog-labelled meloxicam suspension, deracoxib, firocoxib or grapiprant are not cat drugs at a smaller dose. Write both rules on the discharge sheet of every senior cat. THE US LABEL POSITION ON MELOXICAM IN CATS, WHICH NO US PAGE MAY OMIT. The FDA-approved feline meloxicam product in the United States is METACAM Injection (NADA 141-219), approved as 'a single, one-time subcutaneous dose of METACAM Injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight' for control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery. It carries a BOXED WARNING, verbatim: 'Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats.' The label further directs that no second meloxicam dose be given, that METACAM Oral Suspension not follow the single injectable dose, and that no other NSAID follow it. There is NO FDA-approved oral NSAID for long-term use in cats; robenacoxib (Onsior) tablets are FDA-approved for cats for postoperative pain for a maximum of three days. JURISDICTION IS THE WHOLE STORY FOR THE SUPPORTIVE RETROSPECTIVE. The often-cited study of long-term low-dose meloxicam in aged cats with DJD was conducted in a feline-only practice in Melbourne, AUSTRALIA, where meloxicam is licensed for long-term feline use; it is 38 cats, 22 of them with stable CKD at the start (IRIS stage 1 n=8, stage 2 n=13, stage 3 n=1), median maintenance dose 0.02 mg/kg/day (range 0.015-0.033), median treatment duration 467 days in the renal group. It found no difference in sequential serum creatinine or urine specific gravity versus untreated controls, and less progression of renal disease in the meloxicam-treated CKD group than in age- and IRIS-matched untreated CKD cats. Its own authors write that 'prospective studies are required to confirm these findings.' What it means: long-term low-dose meloxicam is not automatically off the table in a STABLE CKD cat in a jurisdiction where that use is licensed. What it does NOT mean: that meloxicam protects kidneys, or that a US veterinarian may read it as permission to dose past the US boxed warning. PetSmartMeds will not say either. NON-NSAID OPTIONS BELONG IN THE SAME CONVERSATION: environmental modification; weight management that is slow, supervised and abandoned if the cat stops eating; and the anti-NGF monoclonal antibody frunevetmab (Solensia), FDA-approved for cats under NADA 141-546 for the control of pain associated with osteoarthritis - stated with its own honest caveat, that its confirmatory effectiveness study did not achieve success as defined by the protocol and FDA approved on the weight of evidence across studies, with modest pivotal effect sizes.

   CONSENSUS GUIDELINE, CATS, PLUS AN FDA BOXED WARNING, PLUS ONE RETROSPECTIVE CASE-CONTROL STUDY THAT MUST NOT BE OVERSOLD OR MOVED ACROSS JURISDICTIONS. The 2024 ISFM/AAFP guideline states that the cat's unique metabolism should be considered when prescribing any medications including NSAIDs, that chronic pain may be challenging to detect in this species, that comorbidities - particularly chronic kidney disease - are common in senior cats, and that management may be complicated by other drugs with potential for interactions with NSAIDs. The meloxicam boxed warning, feline indication and single-dose instruction are quoted from the current METACAM Injection US label, NADA 141-219. Gowan 2011 is a retrospective case-control study from a single Australian feline practice, n=38 with 22 CKD cats concentrated in IRIS stages 1-2, and is hypothesis-generating only.

   Taylor S, Gruen M, KuKanich K, Lascelles BDX, Monteiro BP, Real Sampietro L, Robertson S, Steagall PV. 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. J Feline Med Surg. 2024;26(4):1098612X241241951. PMID 38587872. METACAM (meloxicam) Injection, Solution US label, NADA 141-219, DailyMed setid ca78caf5-2b47-46c1-abec-0f925b39f455. Gowan RA, Lingard AE, Johnston L, Stansen W, Brown SA, Malik R. Retrospective case-control study of the effects of long-term dosing with meloxicam on renal function in aged cats with degenerative joint disease. J Feline Med Surg. 2011;13(10):752-61. PMID 21906984, https://doi.org/10.1016/j.jfms.2011.06.008. Solensia (frunevetmab) FDA approval, NADA 141-546.

10. Keep a written nephrotoxic-exposure list in the record, and name the combination that decompensates these cats

    Ensayo controlado en esta especie

    A CKD cat is a cat with no renal reserve, and most acute-on-chronic crises are things that were given rather than things that happened. AVOID, OR USE ONLY WITH A SPECIFIC INDICATION AND MONITORING: aminoglycoside antibiotics (gentamicin, amikacin); iodinated contrast media for imaging; any human NSAID or analgesic from the owner's cabinet; any NSAID dispensed for a dog; and - in a species that cannot glucuronidate it - acetaminophen / paracetamol in any amount at all. THE COMBINATION TO NAME OUT LOUD is the so-called triple whammy: an NSAID plus a RAAS blocker (an ACE inhibitor such as benazepril, or an ARB such as telmisartan) plus a diuretic such as furosemide. Each of the three removes a different compensatory mechanism the kidney uses to defend glomerular filtration when perfusion falls, and this protocol starts CKD cats on the middle one of the three. If an NSAID or a diuretic has to be added to a cat already on telmisartan or benazepril, do it as a deliberate decision with a recheck of creatinine, potassium and hydration booked before the drug is dispensed - not as a refill. Also treat dehydration as a drug interaction: an anaesthetic, a day of not drinking, a vomiting episode or a hot car turns a tolerated RAAS blocker into iatrogenic azotaemia. Ask the owner what else is in the house at every visit, and give them explicit permission to call before adding anything at all, including supplements and over-the-counter products.

    GUIDELINE-DERIVED AND MECHANISTIC, STATED AS SUCH. The 2024 ISFM/AAFP NSAID guidelines state that management of chronic pain may be complicated by prescription of other drugs with the potential for interactions with NSAIDs, and that comorbidities - particularly CKD - are common in senior cats (PMID 38587872). The ISFM CKD guidelines require repeat evaluation with therapy adjusted to individual needs (PMID 26936494). The acetaminophen prohibition rests on primary feline pharmacogenetic data (Court & Greenblatt, PMID 10862526 and PMID 9174118), cited in the safety section. PetSmartMeds did NOT locate a feline clinical study quantifying triple-whammy risk in cats; the combination is therefore published as a mechanistic caution and a monitoring rule, not as a quantified feline risk estimate.

    Taylor S et al. 2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats. J Feline Med Surg. 2024;26(4). PMID 38587872. Sparkes AH et al. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016;18(3):219-39. PMID 26936494. Feline acetaminophen pharmacogenetics: Court MH, Greenblatt DJ. Pharmacogenetics. 2000;10(4):355-69. PMID 10862526.

11. Nutraceutical adjunct - one real randomised trial exists, and its limits are as important as its result

    Evidencia preliminar

    A single randomised trial supports one specific botanical adjunct fed on top of a renal diet. It is an adjunct to the diet, not a substitute for it, and it has no survival data behind it. If an owner wants to add something, this is the only feline CKD nutraceutical in this protocol with a randomised trial attached - and adding it is still a conversation with the clinic first, not a purchase.

    CAT DATA, RANDOMISED CONTROLLED TRIAL, n=34, 90 DAYS, INDUSTRY-AFFILIATED. Thirty-four client-owned neutered cats with IRIS stage II-III CKD were randomised to a control renal diet (n=17) or the identical diet plus tablets containing Lespedeza spp. 0.0588%, Vaccinium macrocarpon 0.0371% and Taraxacum officinale 0.0231% (n=17) for 90 days. BOTH diets improved CKD signs. In the nutraceutical arm, creatinine, BUN, total protein and AST decreased significantly, as did urine turbidity score, colour score and total protein. No adverse effects were reported. Limits that must be published with the result: 90 days only, no survival or uraemic-episode endpoint, n=34, and authors affiliated with SANYpet S.p.a / Forza10, the diet manufacturer. This may NOT be extrapolated to 'slows CKD progression'.

    Di Cerbo A, Iannitti T, Guidetti G, Centenaro S, Canello S, Cocco R. A nutraceutical diet based on Lespedeza spp., Vaccinium macrocarpon and Taraxacum officinale improves spontaneous feline chronic kidney disease. Physiol Rep. 2018;6(12):e13737. PMID 29906338.

12. Assess quality of life at every visit, and have the end-of-life conversation before it is an emergency

    Ensayo controlado en esta especie

    CKD is progressive and, in its advanced stages, fatal - renal disorder was the second most commonly attributed cause of death across all ages in a large UK primary-care study. A protocol that never mentions this leaves the owners of IRIS stage 4 cats without the one conversation they most need. Make quality of life a measured item, not a feeling: use the owner-completed CatQoL alongside the clinical numbers (see monitoring), and record body weight and body condition at every visit. Name in advance the things that will prompt a serious talk - persistent inappetence despite appetite support, uncontrolled nausea or vomiting, repeated uraemic crises, a cat that will no longer accept the interventions it needs, withdrawal from the household, and an owner who can no longer sustain the care. The ISFM consensus panel's own framing is that maintaining quality of life is of paramount importance and that it may be necessary to prioritise therapy given an understanding of what is likely to most benefit the individual patient - which sometimes means doing less. Tell owners early that planned, unhurried euthanasia at home or in a quiet consult room is a legitimate and humane endpoint of this disease, that hospice-style palliative care is a real option, and that choosing comfort over further testing is not giving up. Say it while the cat is still stable, so the decision is not being made for the first time at 2 a.m.

    GUIDELINE FRAMING PLUS POPULATION MORTALITY DATA. The ISFM consensus guidelines state that maintaining quality of life is of paramount importance and that therapy may need to be prioritised according to what is likely to most benefit the individual patient (PMID 26936494). Mortality context: renal disorder accounted for 12.1% of attributed causes of death, second only to trauma at 12.2%, among a random sample of 4,009 confirmed deaths drawn from 118,016 cats attending 90 English primary-care practices (PMID 24925771). The CatQoL instrument was psychometrically validated in and against CKD cats (PMID 26567089). PetSmartMeds has NOT located a validated feline end-of-life decision instrument or any quality-of-life score threshold for euthanasia, and publishes no scoring cut-off; the prompts above are original clinical-conversation wording, not a validated tool.

    Sparkes AH et al. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016;18(3):219-39. PMID 26936494. O'Neill DG, Church DB, McGreevy PD, Thomson PC, Brodbelt DC. Longevity and mortality of cats attending primary care veterinary practices in England. J Feline Med Surg. 2015;17(2):125-33. PMID 24925771, https://doi.org/10.1177/1098612X14536176. Bijsmans ES et al. J Vet Intern Med. 2016;30(1):183-91. PMID 26567089.

13. Do NOT substitute a biologic for any of the above

    Aprobado / respaldado por guías

    Stem cell, exosome and peptide products have no demonstrated benefit in cats with naturally occurring CKD, and one feline formulation has a documented harm signal. The opportunity cost is the real danger: a cat on cell infusions instead of a renal diet, phosphate control and blood-pressure management is receiving the one intervention that failed its randomised trial in place of the one that passed. See the biologic section of this protocol for the full citation set.

    CAT DATA, RANDOMISED PLACEBO-CONTROLLED TRIAL - NULL. No significant change in serum creatinine, BUN, potassium, phosphorus, GFR by nuclear scintigraphy, UPC or packed cell volume in cats treated with allogeneic adipose MSCs (n=6 treated). Individual GFR changes in treated cats were 12%, 8%, 8%, 2%, -13% and -67%, versus 16%, 36% and 0% in placebo cats - the best placebo cat outperformed every treated cat.

    Quimby JM, Webb TL, Randall E, Marolf A, Valdes-Martinez A, Dow SW. Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats. J Feline Med Surg. 2016;18(2):165-71. PMID 25784460.

Cómo se diagnostica

• Confirm persistence, then stage. IRIS staging is based on at least two blood creatinine measurements taken in a fasted, well-hydrated, clinically stable patient, interpreted alongside urine specific gravity; SDMA is used by IRIS as an adjunctive marker where the laboratory reports it. A single azotaemic value in a dehydrated or stressed cat stages nothing (International Renal Interest Society staging guidelines, http://www.iris-kidney.com/guidelines/; ISFM consensus guidelines, PMID 26936494).
• Substage at every visit with urine protein:creatinine ratio and indirect systolic blood pressure. Magnitude of proteinuria is among the factors reported as related to progression (Brown 2016, PMID 26869151), and blood pressure measurement and target-organ assessment follow the 2018 ACVIM consensus statement (Acierno 2018, PMID 30353952, https://doi.org/10.1111/jvim.15331). Include a fundic examination: target-organ damage, including retinal lesions, can already be present at the time hypertension is first identified, and the ISFM hypertension guidelines state that routine blood pressure monitoring is generally performed infrequently, probably leading to underdiagnosis - so examine the fundus rather than waiting for signs (Taylor 2017, PMID 28245741, https://doi.org/10.1177/1098612X17693500).
• Actively exclude the treatable mimics and contributors before accepting 'idiopathic CKD': dehydration and other pre-renal causes, hyperthyroidism (total T4, with the knowledge that each disease masks the other - Geddes 2022, PMID 35481810), pyelonephritis (urine culture, not just sediment), ureteral or renal calculi, lower urinary tract obstruction, and hypercalcaemia.
• Baseline minimum database: CBC (for non-regenerative anaemia and PCV), full biochemistry with phosphate, potassium, total and ideally ionised calcium, urinalysis with specific gravity and sediment, quantitative UPC, and urine culture. Repeat the panel that matters at each recheck rather than the whole panel every time.
• Image the urinary tract. Abdominal ultrasound and/or radiographs for renal size and asymmetry, pyelectasia, nephroliths and ureteroliths. An obstructed ureter in a cat carrying a CKD label is a surgical problem, not a dietary one.
• Screen deliberately for concurrent degenerative joint disease and for chronic pain, because the co-occurrence with CKD is far higher than chance and it dictates which analgesic is acceptable (Marino 2014, PMID 24217707; 2024 ISFM/AAFP NSAID guidelines, PMID 38587872).
• Take a full home-medication history, including anything the owner has given from their own medicine cabinet, anything dispensed for another pet in the household, and every supplement. Ask the question explicitly rather than waiting to be told; owners of a stiff, sore old cat reach for what is in the bathroom, and acetaminophen / paracetamol, ibuprofen, naproxen, aspirin and canine NSAIDs are all reasons a CKD cat decompensates.
• Auscultate the thorax and, where indicated, screen the heart before prescribing home subcutaneous fluids, because occult cardiomyopathy is the reason a well-intentioned home fluid regimen produces a dyspnoeic cat.
• Record body weight and body condition score at every single visit and plot them. Weight loss commonly precedes a measurable creatinine change and is the earliest reliable signal that the plan needs revisiting.